摘要
目的 探究盐酸依托必利片治疗对消化性溃疡患者的炎症因子、胃蛋白酶原表达的影响.方法 前瞻性选取自2022年5月至2023年5月铜川矿务局中心医院收治的140例消化性溃疡患者作为研究对象,依据随机数字表法将患者分为对照组和观察组,各70例.对照组予以常规治疗(如口服奥美拉唑肠溶胶囊、胶体果胶铋胶囊;合并幽门螺杆菌感染者,口服阿莫西林胶囊、口服克拉霉素片),观察组在对照组治疗的基础上,加用盐酸依托必利片治疗,两组疗程均为14 d.比较两组患者的临床疗效,比较并检测两组患者治疗前及疗程结束后1 d的血清白细胞介素(IL)-1β、IL-2、IL-6、肿瘤坏死因子-α(TNF-α)、胃泌素17(G17)、胃蛋白酶原(PG)Ⅰ、PGⅡ水平,并比较两组不良反应发生情况.结果 观察组临床总有效率为95.71％,高于对照组(87.14％),差异有统计学意义(P＜0.05).疗程结束后1 d,两组血清IL-1β、IL-2、IL-6、TNF-α水平均较治疗前降低,且观察组疗程结束后1 d的血清IL-1β、IL-2、IL-6、TNF-α 水平分别为(32.12±3.27)ng/L、(30.12±4.27)ng/L、(28.74±3.25)ng/L、(22.30±2.83)μg/mL,均低于对照组[(46.87±5.14)ng/L、(43.25±6.18)ng/L、(41.35±6.51)ng/L、(36.47±4.70)μg/mL],差异均有统计学意义(P＜0.05).疗程结束后1 d,两组血清G17、PGⅡ水平均较治疗前降低,血清PG Ⅰ水平均较治疗前升高,差异均有统计学意义(P＜0.05);观察组疗程结束后1 d的血清G17、PGⅡ水平分别为(14.26±2.03)pmol/L、(14.53±4.32)μg/L,均低于对照组[(18.79±3.78)pmol/L、(20.27±6.58)μg/L],PG Ⅰ 水平为(125.85±25.72)μg/L,高于对照组[(105.16±17.84)μg/L],差异均有统计学意义(P＜0.05).两组患者的不良反应发生率比较,差异无统计学意义(P＞0.05).结论 消化性溃疡患者使用盐酸依托必利片效果显著,可降低炎症因子的表达水平,改善胃蛋白酶原表达,且安全性较高.
Abstract
Objective To explore the effect of etopride hydrochloride tablets on the expression of inflammatory factors and pepsinogen in patients with peptic ulcer.Methods A total of 140 patients with peptic ulcer admitted to Tongchuan Mining Bureau Central Hospital from May 2022 to May 2023 were prospectively selected as the research objects.According to the random number table method,the patients were divided in-to the control group and the observation group,with 70 cases in each group.The control group received conventional treatment(such as oral ome-prazole enteric capsule and colloidal pectin bismuth capsule;infected with Helicobacter pylori,oral amoxicillin capsule and oral clarithromycin tab-let).The observation group was treated with ethopilide hydrochloride tablet on the basis of the control group.The course of both groups was 14 d.The clinical efficacy of the two groups was compared.The levels of serum interleukin(IL)-1 β,IL-2,IL-6,tumor necrosis factor-α(TNF-α),gastrin 17(G17),pepsinogen(PG)Ⅰ and PG Ⅱ before treatment and 1 d after treatment were detected and compared between the two groups,and the incidence of adverse reactions was compared between the two groups.Results The total effective rate of the observation group was 95.71％,which was higher than that of the control group(87.14％),and the difference was statistically significant(P＜0.05).One day after the end of treatment,the levels of serum IL-1 β,IL-2,IL-6 and TNF-α in the two groups were lower than those before treatment,and the levels of serum IL-1β,IL-2,IL-6 and TNF-α in the observation group were(32.12±3.27)ng/L,(30.12±4.27)ng/L,(28.74±3.25)ng/L and(22.30±2.83)μg/mL,respectively,which were lower than the control group[(46.87±5.14)ng/L,(43.25±6.18)ng/L,(41.35±6.51)ng/L,(36.47±4.70)μg/mL],the differences were statistically significant(P＜0.05).One day after the end of treat-ment,the levels of serum G17 and PG Ⅱ in the two groups were lower than those before treatment,and the levels of serum PGI were higher than those before treatment,the differences were statistically significant(P＜0.05).The levels of serum G17 and PG Ⅱ in the observation group were(14.26±2.03)pmol/L and(14.53±4.32)µg/L,respectively,which were lower than those in the control group[(18.79±3.78)pmol/L,(20.27±6.58)μg/L],and the level of PGI was(125.85±25.72)μg/L,which was higher than that in the control group[(105.16±17.84)μg/L],the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Patients with peptic ulcer using etopride hydrochloride tablets has a significant effect,reduce the ex-pression level of inflammatory factors,improve the expression of pepsinogen,and has a high safety.
维普
万方数据